FDA Targets Boosting Adverse Event Review ‘Accuracy And Efficiency’
This article was originally published in The Tan Sheet
The agency seeks academic institutions and commercial organizations with tools to triage and review post-marketing adverse event drug product case reports submitted to the Adverse Event Reporting System.
You may also be interested in...
Agency's final rule defines protein based on size of amino acid sequence, irrespective of method of manufacture, saying this 'bright-line rule' provides regulatory certainty.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.